Abstract 190P
Background
Glioblastoma is the most frequent and aggressive primitive brain cancer, associated with dreadful prognosis. This project focuses on a protein called B7H3, member of the B7 « immune checkpoint » protein family. Two isoforms of B7H3 protein (i.e. 2Ig and 4Ig) are produced by alternative splicing and expressed at the cell membrane. Of note, the ectodomain of B7H3 exists as a soluble protein. B7H3 expression in several cancers is associated with poorer prognosis and increased aggressiveness, however its precise role in immune cell modulation in the context of glioblastoma remains elusive.
Methods
Using a murine glioblastoma cell line (CT2A), we allografted immunocompetent mice with CT2A glioma cells overexpressing (OE) the 2Ig isoform of B7H3 (vs cells with control vector). We also engineered a human cell line (U87 OE 2Ig B7H3 vs control vector) to decipher the role of the B7H3 protein on immune cell modulation. Finally patient-derived glioblastoma stem-like cells (GSCs) were used for additional in vitro experiments.
Results
We observed a slight increase in survival in CT2A OE-B7H3 mice, which surprisingly indicated a tumor suppressive effect. We are currently reproducing the experiment using another murine cell line (GL261). Conversely, in vitro coculture experiments revealed no impact of B7H3 on T cell activation or apoptosis, but preliminary results suggest that B7H3 lowers T cell proliferation in vitro. We showed that patient-derived GSCs release soluble B7H3 in the extracellular space and is especially found on extracellular vesicles (EVs).
Conclusions
These results suggest that B7H3 may exert diverse functions in different aspects of glioblastoma immunogenicity. We are exploring the roles of B7H3 isoforms as well as the role it could play on glioblastoma cell-derived EVs, to understand its impact on the immune system.
Legal entity responsible for the study
The authors.
Funding
FNRS, Télévie, Fondation Léon Frédéricq.
Disclosure
G. Jerusalem: Financial Interests, Personal, Advisory Board: Novartis, Roche, Pfizer, BMS, Lilly, AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Novartis, Pfizer, BMS, Lilly, AstraZeneca, Seagen; Financial Interests, Personal, Steering Committee Member: Novartis, AZ/Daiichi Sankyo, BMS; Financial Interests, Institutional, Local PI: Novartis, Roche, Syneos Health, Iqvia, TRIO, Bayer, MSD, IBCSG, PRA, Eli Lilly, PPD, Theradex, ABCSG, Modra, AstraZeneca, Odonate Therapeutics, BMS, ICON, Boeringer, Quintiles, Pfizer, Lilly, Daiichi Sankyo, Seagen, MedImmune; Non-Financial Interests, Personal, Member: ASCO, BSMO; Other, Personal, Other, Medical writer support: MedImmune, Novartis, Roche, Lilly, Amgen, BMS, AstraZeneca, Merck, Pfizer; Other, Personal, Other, Support for attending meetings and/or travel: Novartis, Lilly, BMS, Roche, Amgen, AstraZeneca, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
146P - A Novel Allosteric Oral Immunotherapy Small Molecule Modulates Adenosine 2A Receptor Signaling and Restores Anti-Tumor Immune Responses
Presenter: David Pejoski
Session: Poster Display
147P - Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020
Presenter: Geneviève Gueguen Dorbes
Session: Poster Display
148P - HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo
Presenter: Kristel Kemper
Session: Poster Display
149P - HLA/SIRPa bispecifics-A novel multitarget therapeutic strategy to induce potent anti-tumor immune responses
Presenter: anahita rafiei
Session: Poster Display
150P - Chemotherapy in combination with Toll-like receptor agonism promoted antitumor immune response in triple negative breast cancer
Presenter: Eunice Dotse
Session: Poster Display
151P - Tumor organoid-derived TIL therapy for colorectal cancer
Presenter: Marc Leushacke
Session: Poster Display
152P - Discovery of best-in-class dual-acting A2AR/A2BR antagonists that are functional in high adenosine environment
Presenter: Nainesh Katagihallimath
Session: Poster Display
153P - Discovery of a Novel, Dual CD73 and PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer
Presenter: James Levin
Session: Poster Display
154P - Computer-aided drug design based on CLDN4 ligand and its biological evaluation in ovarian cancer
Presenter: Yi Xu
Session: Poster Display
155P - A Phase 1 Study Exploring the Safety and Tolerability of the Small-Molecule PD-L1 Inhibitor INCB099280 in Select Advanced Solid Tumors
Presenter: Hans Prenen
Session: Poster Display